| 治疗遗传性卵巢癌的新药——奥拉帕尼 |
| 投稿时间：2015-02-02 修订日期：2015-04-29 点此下载全文 |
| 引用本文：唐跃年,金樑,孙朝荣.治疗遗传性卵巢癌的新药——奥拉帕尼[J].药学实践杂志,2015,33(4):373~375 |
| 摘要点击次数: 2931 |
| 全文下载次数: 1475 |
|
|
| 中文摘要:奥拉帕尼(olaparib)是英国阿斯利康公司研发的一种多聚腺苷二磷酸酯核糖聚合酶强抑制剂,通过抑制基因同源重组缺陷,合成杀灭突变的癌细胞,可用于治疗有特异性DNA修复缺陷的癌症,是治疗2种易感基因BRCA1和BRCA2缺损的晚期卵巢癌药物。奥拉帕尼可以选择性杀死癌细胞而又不损害正常细胞,较之传统的化疗手段,其不良反应小得多。 |
| 中文关键词:奥拉帕尼 遗传性 卵巢癌 |
| |
| Olaparib: a new drug for hereditary ovarian cancer treatment |
|
|
| Abstract:Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, and was developed by AstraZeneca Pharmaceuticals LP. Olaparib has therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway. Olaparib is an available therapy option for ovarian cancer patients with deficiencies in the BRCA1 and BRCA2 genes. Olaparib can selectively kill cancer cells without compromising normal cells. Compared to traditional chemotherapy means, adverse reactions are much smaller. |
| keywords:olaparib hereditary ovarian cancer |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
